| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.YGYNO.2019.05.018 |
| P698 | PubMed publication ID | 31285082 |
| P2093 | author name string | Satoshi Yamaguchi | |
| Kazuhiro Suzuki | |||
| Shoji Nagao | |||
| Takashi Shibutani | |||
| Hiroko Yano | |||
| Takaya Shiozaki | |||
| Kasumi Yamamoto | |||
| Kazuko Matsuoka | |||
| Miho Kitai | |||
| Tomoatsu Jimi | |||
| P2860 | cites work | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 |
| Tumor angiogenesis | Q29614938 | ||
| Prediction of creatinine clearance from serum creatinine | Q29615603 | ||
| Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer | Q29622818 | ||
| Carboplatin dosage: prospective evaluation of a simple formula based on renal function | Q33429552 | ||
| Improved survival with bevacizumab in advanced cervical cancer | Q33566222 | ||
| Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies | Q34599824 | ||
| Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). | Q38653061 | ||
| Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505. | Q48047438 | ||
| Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | Q60142201 | ||
| P433 | issue | 3 | |
| P921 | main subject | bevacizumab | Q413299 |
| carboplatin | Q415588 | ||
| paclitaxel | Q423762 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 554-557 | |
| P577 | publication date | 2019-07-05 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer | |
| P478 | volume | 154 |
Search more.